In glioblastoma, breast cancer, and hepatocellular carcinoma (HCC) [50], PRMT2 acts as a putative oncogene, with its high expression promoting cell proliferation and inhibiting apoptosis through catalyzing H3R8me2a (such as activating Bcl2 expression). Here, PRMT2 is linked to breast carcinoma.